European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and telecommunications company Nokia (NOK), which were up 2.4% and 1.6% respectively. They were followed by petroleum refiner Equinor (EQNR) and financial services company Banco Santander (SAN), which increased 1.4% and 1.1% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which shed 10% and 8.7% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Ascendis Pharma (ASND), which lost 3.3% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which rose 8.2% and 6.9% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which advanced 5% and 3.2% respectively.
The decliners from the UK and Ireland were led by communications company WPP (WPP) and biopharmaceutical company Bicycle Therapeutics (BCYC), which dropped 5.7% and 4.2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were down 3.6% and 3.5% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。